SMN2 and proximal spinal muscular atrophy: A small open-label clinical trial of valproate in SMA type III/IV patients reported increase of muscle strength and function and another study demonstrated increased SMN2 mRNA levels following valproate treatment in SMA patients and carriers, although the effect was variable (Brichta et al., 2006; Weihl et al., 2006).